Asset Details
Do you wish to reserve the book?
80例复合型小细胞肺癌的临床分析
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
80例复合型小细胞肺癌的临床分析
Do you wish to request the book?
80例复合型小细胞肺癌的临床分析
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
80例复合型小细胞肺癌的临床分析
2015
Overview
背景与目的复合型小细胞肺癌（combined small cell lung cancer,C-SCLC）的检出率逐年增高,但其相关报道仍较少,本研究探讨C-SCLC的临床病理特征与预后的关系,分析其治疗现状。方法回顾性分析2006年1月-2011年12月间80例病理证实的C-SCLC患者的资料,采用Kaplan-Meier法计算生存率,Log-rank法进行单因素预后分析,Cox风险回归模型分析影响总生存（overall survival,OS）的因素。结果全组的OS为0.3个月-81.4个月,中位OS为26.2个月。单因素分析显示：性别、治疗前卡氏评分、肿瘤直径、分期是影响OS的预后因素（P〈0.05）。多因素分析显示,只有TNM分期是独立的影响OS的因素（P=0.015）。全组多数患者（75.0%）采取综合模式治疗,以铂类药物为基础的联合化疗是主要的治疗方法,采用SCLC的化疗方案或非小细胞肺癌的方案对患者生存的影响无统计学意义（P〉0.05）。结论 C-SCLC是一种特殊类型的肺混合性癌,治疗应采用以铂类为基础的化疗为主的综合治疗模式,TNM分期是独立的预后影响因素。
We currently cannot retrieve any items related to this title. Kindly check back at a later time.